Trial Profile
A Phase 1 Dose Escalation Study of OMP-59R5 in Subjects With Solid Tumors.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Feb 2019
Price :
$35
*
At a glance
- Drugs Tarextumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors OncoMed Pharmaceuticals
- 28 Dec 2018 Results evaluating the safety, pharmacokinetics, immunogenicity,and preliminary efficacy of tarextumab in patients with advanced malignancies published in the Investigational New Drugs
- 09 Apr 2013 Status changed from active, no longer recruiting to completed, according to OncoMed Biosciences.
- 28 Mar 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.